Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy

Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy

Item
http://www.wikidata.org/entity/Q26824268
Antibiotics in the clinical pipeline at the end of 2015.Delafloxacin: design, development and potential place in therapyIn Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance.The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase.In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure InfectionsManaging the oncologic patient with suspected pneumonia in the intensive care unit.Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.New treatment options for lower respiratory tract infections.In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections.Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function.Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study.Safety of Delafloxacin: Focus on Adverse Events of Special Interest
P2860

Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy

Item
http://www.wikidata.org/entity/Q26824268
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Delafloxacin, a non-zwitterion ...... dynamics and clinical efficacy
@ast
Delafloxacin, a non-zwitterion ...... dynamics and clinical efficacy
@en
Delafloxacin, a non-zwitterion ...... dynamics and clinical efficacy
@nl
type
label
Delafloxacin, a non-zwitterion ...... dynamics and clinical efficacy
@ast
Delafloxacin, a non-zwitterion ...... dynamics and clinical efficacy
@en
Delafloxacin, a non-zwitterion ...... dynamics and clinical efficacy
@nl
prefLabel
Delafloxacin, a non-zwitterion ...... dynamics and clinical efficacy
@ast
Delafloxacin, a non-zwitterion ...... dynamics and clinical efficacy
@en
Delafloxacin, a non-zwitterion ...... dynamics and clinical efficacy
@nl
P1433
P1476
P2093
P2860
P304
P31
P3181
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P3181
P356
P1433
P1476
Delafloxacin, a non-zwitterion ...... dynamics and clinical efficacy
@en
P2093
P2860
P304
P31
P3181
P356
P407
P433
P478
P50
P577
P5875
P698
P921